Tempus AI, Inc. (TEM) Income Tax Expense
The tax expense for Tempus AI, Inc. (TEM) is $-51.68 Million with a year-over-year change of -19530.08%. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.
TEM Tax Expense Chart
Current Tax Expense
$-51.68M
$-51.68 Million
Year-over-Year Change
-19530.08%
vs. $266,000 prior year
Historical Data
7
Years of data available
Annual Tax Expense History
| Year | Tax Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $-51.68M | $-51.95M | -19530.08% |
| 2024 | $266,000 | $-22,000 | -7.64% |
| 2023 | $288,000 | +$222,000 | +336.36% |
| 2022 | $66,000 | +$66,000 | — |
| 2021 | $0 | +$0 | — |
| 2020 | $0 | +$0 | — |
| 2019 | $0 | — | — |
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky